Omicron News and Research

RSS

Clec9A-RBD immunization could trigger robust and sustained systemic and mucosal immune responses against rapidly evolving SARS-CoV-2 variants

Researchers assessed the impact of a single-dose dendritic cell vaccine candidate on immune responses against SARS-CoV-2.

23 Feb 2023

Study shows antibody-dependent SARS-CoV-2 transmission and pathogenesis

Researchers reported that some monoclonal nAbs directed against distinct RBD epitopes nested inside the SARS-CoV-2 S could substitute ACE2 as a receptor and support fusion between viral and host cell membranes facilitating viral infectivity.

23 Feb 2023

CDC evaluation of the efficacy of monovalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection in 3 to 5-year-olds

The complete primary series monovalent mRNA vaccines protect children aged three to five against symptomatic infection for up to four months.

22 Feb 2023

RBD-NTD-subunit protein vaccine provides a promising booster vaccination strategy capable of protecting against known SARS-CoV-2 variants

Researchers assessed the impact of SARS-CoV-2 spike NTD incorporation into the RBD protein vaccine.

22 Feb 2023

New analysis shows how convalescent plasma can be used as effective, low-cost COVID-19 treatment

Three years into the COVID-19 pandemic, new variant outbreaks continue to fuel economic disruptions and hospitalizations across the globe.

22 Feb 2023

MHRA authorizes new version of the Moderna ‘bivalent’ Covid vaccine

Authorization has today been granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for a new version of the Moderna 'bivalent' Covid vaccine (Spikevax) that targets both the original strain of SARS-CoV-2 and the Omicron BA.4 and BA.5 sub-variants.

21 Feb 2023

Prior COVID highly protective against severe disease ten months post-infection

In a recent study published in the Lancet, researchers performed a systematic review of scientific literature published from inception up to September 31, 2022, that documented the reduction in risk of coronavirus disease 2019 (COVID-19) among individuals with a prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vis-à-vis those with no COVID-19 history.

19 Feb 2023

After a previous BA.1 infection, Omicron BA.4/5 infection is more likely than BA.2

In a recent study published in the journal Eurosurveillance, researchers investigated whether prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or coronavirus disease 2019 (COVID-19) vaccination protected against SARS-CoV-2 Omicron variant of concern (VOC) BA.4/5 sub-VOC or BA.2 sub-VOC infections.

19 Feb 2023

How effective has the bivalent booster COVID vaccination been?

In a recent study published in the journal Eurosurveillance, researchers estimated the effectiveness of bivalent messenger ribonucleic acid (mRNA) vaccines targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.1 subvariant and the original Wuhan-Hu1 strain against Omicron infections in the vaccinated population of the Netherlands between 26 September and 19 December 2022.

19 Feb 2023

Epidemic dynamics of the SARS-CoV-2 Omicron variant in China during the transition from 'zero-COVID' to little-to-no intervention efforts

Researchers quantified the magnitude and rate of the SARS-CoV-2 Omicron variant outbreak in China following the abrupt exit from the ‘zero-COVID’ guidelines.

17 Feb 2023

Research reports full efficacy of Sotrovimab against BQ.1.1 viral replication in a non-human primate challenge model

Researchers used a non-human primate model to show that Sotrovimab, a commercial mAb also known as Xevudy, was fully effective against SARS-CoV-2 Omicron BA.5 sub-lineage and its derivatives, such as BQ.1.1.

17 Feb 2023

The relationship between antibody titers and incident SARS-CoV-2 infection among recipients of a primary vaccine series

Researchers evaluated whether serologic testing could help estimate the risk of SARS-CoV-2 infection in vaccinated individuals who had not received a booster dose.

17 Feb 2023

Omicron has higher risk of in-hospital mortality compared to influenza

In a recent study published in the journal JAMA Network Open, researchers compared the hospital outcomes of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant with those of influenza patients in Switzerland, assess the current disease burden due to coronavirus disease 2019 (COVID-19).

16 Feb 2023

Nirmatrelvir–ritonavir found to lower COVID-19 severity outcomes

Researchers evaluated the effectiveness of nirmatrelvir–ritonavir in preventing coronavirus disease 2019 (COVID-19) severity outcomes during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant predominance.

16 Feb 2023

Cohort study examines the incidence of SARS-CoV-2 rebound in patients on oral antivirals

Researchers performed a retrospective population-wide cohort study using anonymized data in Hong Kong, China, between February 26 and July 3, 2022.

16 Feb 2023

COVID-19 is associated with higher diabetes and hypertension risk

In a recent study published in the journal JAMA Network Open, researchers determined new-onset diabetes, hypertension, and hyperlipidemia, all cardiometabolic disorders in adult coronavirus disease 2019 (COVID-19) patients under treatment in California, United States of America (USA) between March 2020 and June 2022.

15 Feb 2023

Nirmatrelvir-ritonavir therapy effective against Omicron BA.4/BA.5

Researchers examine non-hospitalized adult patients with COVID-19 treated with nirmatrelvir-ritonavir.

15 Feb 2023

New insights into the driving factors of COVID-19 dynamics in England

In a recent study posted to the medRxiv* preprint server, researchers provided quantitative estimates of population-level drivers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and infection severity by fitting coronavirus disease 2019 (COVID-19) epidemiological surveillance data from England into dynamic transmission models.

15 Feb 2023

Bivalent and monovalent mRNA boosters induce similar antibody response against Omicron subvariants

A study conducted by US-based scientists claims that bivalent mRNA booster vaccines do not have any added benefits over monovalent booster vaccines in terms of inducing robust and durable neutralizing antibody response against omicron subvariants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Feb 2023

NIH initiates a clinical trial evaluating an investigational antiviral for treatment of COVID-19

The National Institutes of Health has initiated a multi-site clinical trial evaluating an investigational antiviral for the treatment of COVID-19.

15 Feb 2023

Omicron News and Research

Clec9A-RBD immunization could trigger robust and sustained systemic and mucosal immune responses against rapidly evolving SARS-CoV-2 variants

Study shows antibody-dependent SARS-CoV-2 transmission and pathogenesis

CDC evaluation of the efficacy of monovalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection in 3 to 5-year-olds

RBD-NTD-subunit protein vaccine provides a promising booster vaccination strategy capable of protecting against known SARS-CoV-2 variants

New analysis shows how convalescent plasma can be used as effective, low-cost COVID-19 treatment

MHRA authorizes new version of the Moderna ‘bivalent’ Covid vaccine

Prior COVID highly protective against severe disease ten months post-infection

After a previous BA.1 infection, Omicron BA.4/5 infection is more likely than BA.2

How effective has the bivalent booster COVID vaccination been?

Epidemic dynamics of the SARS-CoV-2 Omicron variant in China during the transition from 'zero-COVID' to little-to-no intervention efforts

Research reports full efficacy of Sotrovimab against BQ.1.1 viral replication in a non-human primate challenge model

The relationship between antibody titers and incident SARS-CoV-2 infection among recipients of a primary vaccine series

Omicron has higher risk of in-hospital mortality compared to influenza

Nirmatrelvir–ritonavir found to lower COVID-19 severity outcomes

Cohort study examines the incidence of SARS-CoV-2 rebound in patients on oral antivirals

COVID-19 is associated with higher diabetes and hypertension risk

Nirmatrelvir-ritonavir therapy effective against Omicron BA.4/BA.5

New insights into the driving factors of COVID-19 dynamics in England

Bivalent and monovalent mRNA boosters induce similar antibody response against Omicron subvariants

NIH initiates a clinical trial evaluating an investigational antiviral for treatment of COVID-19

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News